Nanoportal Biotech and OriGene Technologies Announce Global Distribution Partnership for ProteanFect™, Marking a Breakthrough in Primary Cell Engineering
Hangzhou, China, November 10, 2025 — Nanoportal Biotech and OriGene Technologies today announced a strategic global distribution partnership (outside Greater China) for ProteanFect™, the first protein coacervate–based transfection reagent. The collaboration brings a new class of delivery chemistry to researchers worldwide and signals a long-anticipated leap forward for primary cell engineering and hard-to-transfect cell models.
For many labs, efficient delivery in primary cells, immune cells, neurons, and certain cancer lines has felt like a ceiling that would not budge. ProteanFect is designed to change that. Early adopters report high transfection efficiency with preserved cell health and streamlined workflows, reducing the trial-and-error that has long slowed programs at the bench and in translational settings.
“Researchers have been waiting for a step change in how we engineer the most biologically relevant cells,” said Xiaofei Gao, PhD, Founder and President of Nanoportal Biotech. “ProteanFect reflects years of work to bring protein coacervate chemistry into a dependable, everyday reagent. Partnering with OriGene means scientists around the world can access this capability right now, backed by OriGene’s proven global logistics, customer support, and deep relationships with front line researchers. We are confident this partnership will scale ProteanFect to every region where primary cell engineering matters.”
“Empowering researchers to tackle difficult biology has always been central to OriGene’s mission,” said Xuan Liu, PhD, Senior Vice President at OriGene Technologies. “ProteanFect represents a true breakthrough made possible by Nanoportal’s remarkable innovation and scientific rigor. Through this collaboration, OriGene is proud to deliver this next-generation solution to scientists worldwide, supported by our extensive global reach and trusted customer service.”
Why this matters now
· Primary cells, engineered with confidence: Reported strong performance in T and NK cells, neurons, and other delicate primary systems while maintaining viability and function
· Hard-to-transfect lines, unlocked: Results in historically resistant cancer and suspension lines suggest broader access to more predictive models
· Less optimization, more science: Simple protocols fit existing culture routines, helping teams move from pilot to scale with fewer bottlenecks
Technical resources
Application notes, quick-start guides, and responsive technical support are available from both partners to help teams transition projects into primary cells and difficult lines with minimal re-tooling.
About Nanoportal Biotech
Nanoportal Biotech is pioneering next-generation gene delivery platforms based on natural biological pathways. Its flagship innovation, ProteanFect™, is the world’s first coacervate-based nucleic acid delivery system, designed to deliver genetic material with unmatched efficiency and safety across a wide range of cell types. Nanoportal is committed to equipping researchers and collaborators with transformative technologies that power the next era of gene and cell therapy research.
About OriGene Technologies
OriGene Technologies, Inc., headquartered in Rockville, MD, is a global research tools company dedicated to advancing biomedical research and drug discovery. With a portfolio of over 1.3 million products—including cDNA clones, recombinant proteins, antibodies, and assays—OriGene provides scientists worldwide with the tools they need to accelerate genomics and proteomics breakthroughs.
